| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 30-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 29-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| IMPAX has a current Overall Rating of A (Highest Rating). | 7 |
$25 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (United States) | 101 |
$169 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Industry Averages: Health, Medicine and Pharmaceuticals (North America) | 103 |
$169 |
| 29-Nov-2009 | Wright Reports |
N/A
| Wright Investors Service Comprehensive Report for Impax Laboratories, Inc. | 44 |
$65 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: AKRX , AOB , AUXL , AVNR , DYAX , IPXL , SCLN , SCMP -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: IMPAX LABS -- IPXL | 1 |
$4 |
0.34% Nasdaq 0.00%
Research Reports
